We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Reconstruction of Digital Nerve Defects in Humans Using an Implanted Silk Nerve Guide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03673449
Recruitment Status : Unknown
Verified March 2020 by Silk Biomaterials srl.
Recruitment status was:  Active, not recruiting
First Posted : September 17, 2018
Last Update Posted : March 18, 2020
Sponsor:
Information provided by (Responsible Party):
Silk Biomaterials srl

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The goal of this study is to ascertain the feasibility and safety of the procedure using SilkBridge - a biocompatible silk fibroin-based scaffold - for the regeneration of sensory nerve fibres and follow it up together with the reinnervation of the target organs (sensory receptors in the skin).

Condition or disease Intervention/treatment Phase
Peripheral Nerve Injury Digital Nerve Hand Device: SilkBridge Not Applicable

Detailed Description:

This is a pre-market, monocentre, first-in-human pilot on adult patients with digital nerve defects. Category C clinical trial, medical devices. The study will be performed in Switzerland.

SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.

SilkBridge will provide surgeons with an implant with unique features, such as easy suturability, full biocompatibility and specific biomimetic properties that enhance cells adhesion and integration of the device with the surrounding tissue.

The study will have a 12 months and 1 week duration per patient, including the follow-up period, and with an expected enrollment period of 15 months.

The study will evaluate 15 adult patients, aged 18-65 years, diagnosed with digital nerve defects (> 5 mm gap) in whom surgical repair may not allow direct suture.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open Label Monocentre Study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Evaluate the Reconstruction of Digital Nerve Defects in Humans Using an Implanted Silk Nerve Guide
Actual Study Start Date : March 22, 2019
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: SilkBridge treatment
Surgery for digital nerve reconstruction with SilkBridge
 Device: SilkBridge
SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety of SilkBridge [ Time Frame: 12 months ]
    Assess type and severity of adverse device effects related to SilkBridge and surgical procedure throughout the follow-up period


Secondary Outcome Measures :
  1. Performance - assess at each study visit versus baseline [ Time Frame: 12 months ]
    Sensory recovery after nerve reconstruction by static and moving 2-point discrimination and Semmes-Weinstein monofilament testing Pain evaluation via a visual analog scale (VAS: scale where patient has to specify level of pain by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no pain while 10 represents the highest level.)

  2. Performance - assess at V5 and at last visit versus opposite control finger [ Time Frame: 6 and 12 months ]
    Sensory recovery by static and moving 2-point discrimination and Semmes-Weinstein monofilament testing

  3. Performance - assess at the last visit [ Time Frame: 12 months ]
    Patient's satisfaction through the Patient Global Impression of Change (PGIC) questionnaire (Patient has to describe the change (if any) in activity limitations, symptoms, emotions and overall quality of life, in relation to its painful condition. 0 value represent no change, 7 a considerable improvement).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • male & female patients between 18 and 65 years of age
  • a traumatic injury or a post-traumatic neuroma of a digital nerve on the palmar side of the hand, between the metacarpophalangeal joint and the distal interphalangeal joint
  • single lesion per finger
  • nerve defect of >5mm
  • nerve treatment initiated within 24 months after nerve injury
  • signed informed consent

Exclusion Criteria:

  • disorders known to affect the peripheral nervous system, such as, but not only, diabetes mellitus, chronic heavy alcohol use, or toxic nerve lesions, or any polyneuropathy
  • an additional injury that could compromise nerve regeneration
  • clinically significant (as defined by the investigator) renal, hepatic, cardiac, endocrine, metabolic, hematologic, autoimmune, or any systemic disease, which may make implementation/interpretation of the protocol or results difficult
  • previous conditions of the hand that could affect the healing of the actual nerve injury
  • complete amputation injury
  • extensive crush injury
  • grossly contaminated wound
  • receiving immunosuppressive or antineoplastic agents within 30 days prior to the enrolment
  • known to be HIV positive
  • known pregnant and lactating females
  • participated in another clinical investigation using an investigational new drug or device (or in the present study) within 30 days prior to enrolment into this investigation
  • uncooperative or unsuitable, e.g. language problems or a suspicion to be unable to attend follow up appointments, for completion of the investigation
  • absence of a healthy opposite finger
  • suspected allergy to silk
  • need of emergency surgery (within 24 hours from injury)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03673449


Locations
Layout table for location information
Switzerland
Klinik für Plastische Chirurgie und Handchirurgie - UniversitätsSpital Zürich
Zürich, Switzerland, 8091
Sponsors and Collaborators
Silk Biomaterials srl
Investigators
Layout table for investigator information
Principal Investigator: Maurizio Calcagni, MD Klinik für Plastische Chirurgie und Handchirurgie - UniversitätsSpital Zürich
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Silk Biomaterials srl
ClinicalTrials.gov Identifier: NCT03673449    
Other Study ID Numbers: SB_DND-01/2018
First Posted: September 17, 2018    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Silk Biomaterials srl:
peripheral nerve injury
nerve guide
silk fibroin
silk
nerve regeneration
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nerve Injuries
Peripheral Nervous System Diseases
Neuromuscular Diseases
 Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries